Actelion receives approval for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension in Australia and New Zealand
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion receives approval for Uptravi (selexipag) for the treatment of
pulmonary arterial hypertension in Australia and New Zealand
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Approval granted by Medsafe in New Zealand on 17 March 2016 and by the TGA
in Australia on 18 March 2016
ALLSCHWIL, SWITZERLAND - 22 March 2016 - Actelion Ltd (SIX: ATLN) announced
today that the Therapeutic Goods Administration (TGA) of Australia and the New
Zealand Medicines and Medical Devices Safety Authority (Medsafe) have granted
approval for the orally active selective IP prostacyclin receptor agonist
Uptravi® (selexipag), originally discovered and synthesized by Nippon Shinyaku,
for the treatment of pulmonary arterial hypertension.
Uptravi is indicated for the treatment of idiopathic PAH, heritable PAH, PAH
associated with connective tissue disease, PAH associated with congenital heart
disease with repaired shunts and PAH associated with drugs and toxins, in
patients with WHO functional class II, III or IV symptoms.
The labels were based in part on the Phase III GRIPHON study, whose main
findings were published in the New England Journal of Medicine in December
2015. This placebo-controlled study, the largest ever in PAH, established the
effectiveness of Uptravi in PAH patients with WHO Functional Class II-III
symptoms. [1]
Simon Eade, Head of Actelion Asia Pacific Region, commented, "The approval of
Uptravi represents a major step forward in disease management for the PAH
communities in both Australia and New Zealand. Until now the options for
treatments targeting the prostacyclin pathway have been limited, and were
burdensome for the patient. Uptravi offers patients an oral treatment that
targets the prostacyclin pathway, opening the way for oral combination therapies
with proven long-term outcome benefits. We will now work to secure reimbursement
and make Uptravi available to patients."
The safety of selexipag has been evaluated in a long-term, Phase III placebo-
controlled study enrolling 1,156 patients with symptomatic PAH. The mean
treatment duration was 76.4 weeks (median 70.7 weeks) for patients receiving
selexipag versus 71.2 weeks (median 63.7 weeks) for patients on placebo. The
exposure to selexipag was up to 4.2 years.
The most commonly reported adverse reactions related to the pharmacological
effects of Uptravi are headache, diarrhoea, nausea and vomiting, jaw pain,
myalgia, pain in extremity, arthralgia, and flushing. These reactions are more
frequent during the up-titration phase. The majority of these reactions are of
mild to moderate intensity.
###
NOTES TO EDITOR:
REGULATORY STATUS OF SELEXIPAG
Market authorization has so far been received from the US FDA (21 December
2015) and Health Canada (20 January 2016), New Zealand's Medsafe (17 March
2016) and Australia's TGA (18 March 2016). Submission of the registration
dossier to other health authorities is ongoing, with regulatory reviews underway
in the European Union, Japan, South Korea, Switzerland, Taiwan and Turkey.
ABOUT UPTRAVI® (SELEXIPAG) [2-7]
Uptravi (selexipag), originally discovered and synthesized by Nippon Shinyaku,
is the only approved oral selective IP receptor agonist administered as tablet,
targeting the prostacyclin pathway in PAH.
Uptravi and its major metabolite selectively target the prostacyclin receptor
(also called IP receptor). The IP receptor is one of 5 major types of prostanoid
receptor (IP, EP, DP, TP, FP). Prostacyclin activates the IP receptor to induce
vasodilation and inhibit proliferation of vascular smooth muscle cells.
ABOUT THE GRIPHON STUDY [1]
GRIPHON, a global, pivotal Phase III study, was designed to demonstrate a
prolongation of time to the first morbidity/mortality event for selexipag
compared to placebo and to evaluate the safety of selexipag in PAH patients.
A total of 1'156 patients were randomized to receive placebo or selexipag in
individualized doses (maximum dose, 1600 mcg twice daily). A primary endpoint
event occurred in 397 patients - 41.6% of those in the placebo group and 27.0%
of those in the selexipag group (hazard ratio in the selexipag group as compared
with the placebo group, 0.60; 99% confidence interval, 0.46 to 0.78; P<0.001).
Disease progression and hospitalization accounted for 81.9% of the events.
Patients received twice daily administration of selexipag or placebo and were
also permitted to receive background therapy of endothelin receptor antagonist
and/or a phosphodiesterase-5 (PDE-5) inhibitor when on a stable dose for at
least 3 months prior to enrollment. At baseline, almost 80% of patients were
receiving oral medication specific for PAH: either an ERA, a PDE-5 inhibitor, or
a combination of the two. The effect of selexipag with respect to the primary
endpoint was similar in the subgroup of patients who were not receiving
treatment for the disease at baseline and in the subgroup of patients who were
already receiving treatment at baseline (including those who were receiving a
combination of two therapies).
Adverse reactions occurring more frequently on Uptravi compared to placebo by
/>=3%, over the course of the study, were headache, diarrhea, jaw pain, nausea,
myalgia, vomiting, pain in extremity, flushing, arthralgia, anemia, decreased
appetite and rash. These adverse reactions are more frequent during the dose
titration phase. Hyperthyroidism was observed in 1% (n=8) of patients on
selexipag and in none of the patients on placebo.
THE ROLE OF THE PROSTACYCLIN PATHWAY [7]
The prostacyclin pathway is one of the 3 best characterized pathways involved in
the pathophysiology and treatment of PAH. Prostacyclin is a prostanoid and
serves as a signaling molecule in the human body. It is produced, like other
vasoactive substances, by endothelial cells. Prostacyclin induces vasodilation,
is anti-proliferative, has anti-inflammatory effects and inhibits platelet
aggregation. In certain disease conditions, the production of prostacyclin by
the endothelium is impaired, allowing for example, the deleterious effects of
excessive levels of endothelin or thromboxane to predominate.
PULMONARY ARTERIAL HYPERTENSION (PAH)
PAH is a chronic, life-threatening disorder characterized by abnormally high
blood pressure in the arteries between the heart and lungs of an affected
individual. The symptoms of PAH are non-specific and can range from mild
breathlessness and fatigue during normal daily activity to symptoms of right
heart failure and severe restrictions on exercise capacity and ultimately
reduced life expectancy.
PAH is one group within the classification of pulmonary hypertension (PH). This
group includes idiopathic PAH, heritable PAH and PAH caused by factors which
include connective tissue disease, HIV infection and congenital heart disease.
The last decade has seen significant advances in the understanding of the
pathophysiology of PAH, which has been paralleled with developments of treatment
guidelines and new therapies. Drugs targeting the three pathways that have been
established in the pathogenesis of PAH are endothelin receptor antagonists
(ERAs), prostacyclin receptor agonists, and phosphodiesterase-5 inhibitors. PAH
treatments have transformed the prognosis for PAH patients from symptomatic
improvements in exercise tolerance 10 years ago to delayed disease progression
today. Improved disease awareness and evidence-based guidelines developed from
randomized controlled clinical trial data have highlighted the need for early
intervention, goal-oriented treatment and combination therapy. Learn more at
http://www.pahuman.com/
ABOUT THE ACTELION / NIPPON SHINYAKU ALLIANCE
Actelion and Nippon Shinyaku entered into an exclusive worldwide alliance in
April 2008 to collaborate on selexipag, a first orally-available, selective
prostacyclin IP receptor agonist for patients suffering from PAH. This compound
was originally discovered and synthesized by Nippon Shinyaku. Actelion is
responsible for global development and commercialization of selexipag outside
Japan, while the two companies will co-develop and co-commercialize in Japan.
Nippon Shinyaku will receive milestone payments based on development stage and
sales milestones as well as royalties on any sales of selexipag.
References
1. Sitbon O et al. Selexipag for the Treatment of Pulmonary Arterial
Hypertension. N Engl J Med 2015; 373:2522-33.
2. Kuwano et al. A long-acting and highly selective prostacyclin receptor
agonist prodrug, NS-304, ameliorates rat pulmonary hypertension with unique
relaxant responses of its active form MRE-269 on rat pulmonary artery. J
Pharmacol Exp Ther 2008;326:691-699.
3. Kuwano K et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-
(methylsulfonyl)acetamide (NS-304), an orally available and long-acting
prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther
2007;322(3):1181-1188.
4. Tetsuo Asaki et al. Selexipag: an oral and selective IP prostacyclin
receptor agonist for the treatment of pulmonary arterial hypertension. J.
Med. Chem., Just Accepted Manuscript. DOI: 10.1021/acs.jmedchem.5b00698.
Web: 20 Aug 2015.
5. Morrison et al. Selexipag: a selective prostacyclin receptor agonist that
does not affect rat gastric function. J Pharmacol Exp Ther 2010;335:249-255.
6. Morrison et al. Differential effects of selexipag and prostacyclin analogs
in rat pulmonary artery. J Pharmacol Exp Ther 2012;343:547-555.
7. Simonneau G, Lang I, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie N.
Selexipag, an oral, selective IP receptor agonist for the treatment of
pulmonary arterial hypertension Eur Respir J 2012; 40: 874-880.
8. Mubarak KK. A review of prostaglandin analogs in the management of patients
with pulmonary arterial hypertension. Respir Med 2010;104:9-21.
NIPPON SHINYAKU
For further information on Nippon Shinyaku please visit:
http://www.nippon-shinyaku.co.jp/english/index.html
ACTELION LTD
Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.
Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our
portfolio of PAH treatments covers the spectrum of disease, from WHO Functional
Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.
Although not available in all countries, Actelion has treatments approved by
health authorities for a number of specialist diseases including Type 1 Gaucher
disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from
systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.
Founded in late 1997, with now over 2,400 dedicated professionals covering all
key markets around the world including Europe, the US, Japan, China, Russia and
Mexico, Actelion has its corporate headquarters in Allschwil / Basel,
Switzerland.
Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks
are legally protected.
For further information please contact:
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
http://www.actelion.com
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment and
research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
Press release PDF:
http://hugin.info/131801/R/1996574/735753.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire
[HUG#1996574]
Unternehmensinformation / Kurzprofil:
Datum: 22.03.2016 - 07:01 Uhr
Sprache: Deutsch
News-ID 459004
Anzahl Zeichen: 14889
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 299 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion receives approval for Uptravi (selexipag) for the treatment of pulmonary arterial hypertension in Australia and New Zealand"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
